Moleculin Biotech says AACR pancreatic cancer conference features new Annamycin trial data
MBRX•Preclinical findings and broader program update
Preclinical findings support activity in pancreatic cancer, including signs the drug may help recruit immune cell killing.
The update broadens the program’s potential beyond AML as Moleculin continues its MIRACLE trial of AnnAraC in relapsed or refractory AML.
New Annamycin data to be presented at scientific meetings
Moleculin Biotech announced new Annamycin data will be presented at three scientific meetings in September 2026.
Two presentations already scheduled in Poland focus on where Annamycin concentrates in the body and how it attacks cancer cells.
An AACR pancreatic cancer presentation is set for Sept. 25-28, with results to be disclosed when the abstract publishes Sept. 25.
